-
Powered by Mission Club, the Deal Board allows Psychedelic Capital virtual event attendees the ability to take part in early-stage investments
-
The first investment opportunity is now open with Med Plant Science Ltd
Psychedelic medicine aims to revolutionize. A whole industry forming around changing the way we think about mental health and the paths towards wellness, with goals no less lofty than shifting the status quo of multi-billion industries like biotech and pharma.
The sector, in general, attracts a more forward-thinking type of individual, one comfortable with re-assessing the ways things are usually done. And is there a higher, more entrenched ivory tower than Wall Street and the investment world?
Which is why Microdose is doing its part in helping democratize investment opportunities. The company has launched the Deal Board, a vehicle for all levels of investors to take part in early-stage investments.
Up to very recently, early investments were limited exclusively to accredited investors. “Community Rounds weren’t always possible or even legal. Raising capital from unaccredited investors was illegal before 2016 and then only really viable as of 2021… New US securities laws called Regulation Crowdfunding permit founders to raise up to $5 million per year from their global network, whether unaccredited or accredited.” (An excerpt from a piece sponsored by major equity crowdfunder WeFunder).
The barriers are starting to come down, but access is still an issue and early opportunities are still mostly reserved for those deeply connected to the investment world. Microdose is hoping to change that, giving everyday investors the chance at early-stage investments in the psychedelic medicine space.
‘’Over the last 18 months of hosting the Psychedelic Capital virtual event series, we’ve seen an ever-increasing desire for attendees to be able to take part in early-stage investments. Today, we’re excited to announce that our attendees’ dreams have become a reality through PsyCap Deal Board, Powered by Mission Club.’’ — said Patrick Moher, President, Microdose Psychedelic Insights
It seems a natural fit: introduce new models of raising capital to help companies with their new models of treating mental health.
The first investment opportunity is now open with Med Plant Science Ltd. Med Plant Science is a biotech company focused on the research and development of medicines based on psychedelic substances. The company is licensed to grow, process, extract, and export psychedelic compounds from plants and mushrooms. Med Plant Science is innovating rapid onset psychedelic medications using patented nano encapsulation technology. This novel approach empowers clinicians to work with more patients and secure better outcomes.
Med Plant Science Initial Financing Round Med Plant Science is raising funds to leverage its research and development licence to develop rapid onset psychedelic medications using patented nano-encapsulation technology. The company is looking to raise $1.8M CAD. For more information on the deal and to participate please visit: https://microdose.buzz/deal/med-plant-science-initial-financing-round/
“By bringing investments directly to the people, we want individual investors to feel as appreciated as family offices. With minimal financial commitment required, we’re opening the doors of early-stage investing to just about everyone.” — Connor Haslam, CEO
The next investment opportunity will be announced during the next Psychedelic Capital event on Thu, May 26. Get tickets to the event here.
